Delisting Of Jazz’s Xyrem Patent In Orange Book Could Spur More Infringement Counterclaims

 
• By Brenda Sandburg
  
Delist
Court rules Jazz's Xyrem patent should be delisted from FDA's Orange Book • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Legal & IP

More from Pink Sheet